Status:
WITHDRAWN
Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Central Centrifugal Cicatricial Alopecia
Eligibility:
FEMALE
18+ years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of this pilot study is to determine if calcipotriol shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). This study aims to evaluate calcipotri...
Detailed Description
Calcipotriol, a vitamin D analog, has been topically used to treat alopecia areata, a form of non-scarring autoimmune alopecia in several studies. It is possible that Vitamin D plays a role in sustain...
Eligibility Criteria
Inclusion
- Women who are eighteen years of age or older
- biopsy-proven and/or clinical diagnosis of CCCA Stage II-IV
- must be on stable treatment without changes for at least 3 months
- Subjects will be recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology.
Exclusion
- Males
Key Trial Info
Start Date :
August 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05416320
Start Date
August 1 2023
End Date
December 1 2023
Last Update
August 31 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157